UNSPSC 51281814: Amrubicin hydrochloride

This classification denotes an anthracycline antibiotic with the molecular formula C25H25NO9.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EUL6MP8FZW, chemically known as 5,12-naphthacenedione, 9-acetyl-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7s,9s)- but more generally known as amrubicin hydrochloride, which bears US NIH Compound Identifier 114897.

UNSPSC 51281814 Amrubicin hydrochloride is a Commodity code that in practice receives little relevant state and local procurement activity aligned with its nominal scope. The recent opportunities posted under this code do not involve amrubicin hydrochloride or oncology pharmaceuticals; instead, they span unrelated categories including naloxone kits, generic multi-source pharmaceuticals and over-the-counter products, and medical/first-aid supplies for emergency response. The mismatch between the code's specific drug designation and the actual procurement mix suggests the code sees minimal legitimate activity or that state and local systems are tagging opportunities with codes that do not reflect the work being bought.

The issuing bodies include state health agencies (Texas Health and Human Services Commission, Minnesota Department of Administration through the MMCAP cooperative purchasing alliance), county public health departments (Seminole County, Florida), and municipal fire services (City of Tampa Fire Department Rescue Division). The geographic spread includes Texas, Minnesota, Florida, and Oregon through cooperative purchasing. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for medical and first-aid supplies to the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. The Tampa procurement is a sheltered-market opportunity exclusively for certified Small Local Business Enterprises with a 5 percent bid discount. Given the consistent misalignment between the code and recent opportunities, this code warrants close attention only if your firm manufactures amrubicin hydrochloride or specific oncology pharmaceuticals; otherwise, the activity posted here does not represent genuine market demand within the code's scope.